Kiniksa Pharmaceuticals International (KNSA) Liabilities and Shareholders Equity (2017 - 2026)

Kiniksa Pharmaceuticals International's Liabilities and Shareholders Equity history runs 10 years deep, the most recent figure standing at $825.3 million for Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 37.7% year-over-year to $825.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.0 billion (up 30.07% YoY) and the FY2025 annual result came in at $763.6 million, up 31.54% from the prior year.
• Liabilities and Shareholders Equity was $825.3 million for Q1 2026 at Kiniksa Pharmaceuticals International, up from $763.6 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $825.3 million in Q1 2026 and bottomed at $210.6 million in Q2 2022.
• A 5-year average of $532.8 million and a median of $526.3 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity dropped 25.77% — and 2023, when it jumped 130.0%.
• Kiniksa Pharmaceuticals International's Liabilities and Shareholders Equity stood at $459.7 million in 2022, then climbed by 14.5% to $526.3 million in 2023, then grew by 10.3% to $580.6 million in 2024, then jumped by 31.54% to $763.6 million in 2025, then increased by 8.07% to $825.3 million in 2026.
• Business Quant data shows KNSA's Liabilities and Shareholders Equity at $825.3 million in Q1 2026, $763.6 million in Q4 2025, and $712.3 million in Q3 2025.